An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma.
dc.contributor.author | McGowan, B | |
dc.contributor.author | Bennett, K | |
dc.contributor.author | Barry, M | |
dc.contributor.author | Owens, M | |
dc.contributor.author | O'Connor, M | |
dc.date.accessioned | 2013-10-03T13:52:31Z | |
dc.date.available | 2013-10-03T13:52:31Z | |
dc.date.issued | 2009-03 | |
dc.identifier.citation | An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma. 2009, 102 (3):73-6 Ir Med J | en_GB |
dc.identifier.issn | 0332-3102 | |
dc.identifier.pmid | 19489193 | |
dc.identifier.uri | http://hdl.handle.net/10147/302664 | |
dc.description.abstract | There are approximately 6,300 people in Ireland with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) and with a fast growing elderly population the incidence of COPD is likely to increase. This study examines the prescribing patterns of medicines dispensed for the management Asthma/COPD in patients over the age of 35 years using the HSE-Primary Care Reimbursement Services (PCRS) prescribing databases. The HSE-PCRS pharmacy claims data, which covers all those over 70 years of age and means tested for those less than 70 years, was analysed for the years 2005/2006. Approximately 26,548 (17.9%) of patients who were prescribed a respiratory drug received inhaled short-acting beta2 agonists in combination with a regular standard-dose inhaled corticosteroid. A further 5,044 (3.4%) were also prescribed a regular inhaled long-acting beta2 agonist (salmeterol or formoterol). A total of 2506 patients (6.2%) on combination therapy were co-prescribed four different anti-asthmatic treatments inclusive of oral prednisolone. A small proportion of the patients prescribed a respiratory drug were co-prescribed nicotine replacement therapy (n = 5177, 3.5%). In total there were 9,728 (6.2%) patients prescribed a mucolytic drug in combination with a respiratory drug and the rate of co-prescribing with antibiotics was 22%. COPD is a debilitating disease that is primarily caused by smoking and is therefore largely preventable. The HSE-PCRS pharmacy claims data is a valuable tool for helping to assess the burden of this disease in the Irish context. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Irish medical journal | en_GB |
dc.subject | ASTHMA | en_GB |
dc.subject | MEDICATION MANAGEMENT | en_GB |
dc.subject.mesh | Adrenal Cortex Hormones | |
dc.subject.mesh | Adrenergic beta-Agonists | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Albuterol | |
dc.subject.mesh | Anti-Asthmatic Agents | |
dc.subject.mesh | Asthma | |
dc.subject.mesh | Bronchodilator Agents | |
dc.subject.mesh | Drug Therapy, Combination | |
dc.subject.mesh | Ethanolamines | |
dc.subject.mesh | Female | |
dc.subject.mesh | Health Expenditures | |
dc.subject.mesh | Health Services | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Incidence | |
dc.subject.mesh | Ireland | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Physician's Practice Patterns | |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | |
dc.title | An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma. | en_GB |
dc.type | Article | en |
dc.contributor.department | Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, James's St, Dublin 8. mcgowab@tcd.ie | en_GB |
dc.identifier.journal | Irish medical journal | en_GB |
refterms.dateFOA | 2018-08-23T08:07:18Z | |
html.description.abstract | There are approximately 6,300 people in Ireland with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) and with a fast growing elderly population the incidence of COPD is likely to increase. This study examines the prescribing patterns of medicines dispensed for the management Asthma/COPD in patients over the age of 35 years using the HSE-Primary Care Reimbursement Services (PCRS) prescribing databases. The HSE-PCRS pharmacy claims data, which covers all those over 70 years of age and means tested for those less than 70 years, was analysed for the years 2005/2006. Approximately 26,548 (17.9%) of patients who were prescribed a respiratory drug received inhaled short-acting beta2 agonists in combination with a regular standard-dose inhaled corticosteroid. A further 5,044 (3.4%) were also prescribed a regular inhaled long-acting beta2 agonist (salmeterol or formoterol). A total of 2506 patients (6.2%) on combination therapy were co-prescribed four different anti-asthmatic treatments inclusive of oral prednisolone. A small proportion of the patients prescribed a respiratory drug were co-prescribed nicotine replacement therapy (n = 5177, 3.5%). In total there were 9,728 (6.2%) patients prescribed a mucolytic drug in combination with a respiratory drug and the rate of co-prescribing with antibiotics was 22%. COPD is a debilitating disease that is primarily caused by smoking and is therefore largely preventable. The HSE-PCRS pharmacy claims data is a valuable tool for helping to assess the burden of this disease in the Irish context. |